Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Mochida Returns Toyama Plant to Meiji Yakuhin
October 20, 2003
-
ARCHIVE Incoming Banyu President Hirate Expresses His Hopes
October 20, 2003
-
ARCHIVE BUSINESS NEWS IN BRIEF
October 20, 2003
-
ARCHIVE NEW PRODUCTS
October 20, 2003
-
ARCHIVE Osaka's ICH-6 to Discuss New GLs for Quality Systems
October 20, 2003
-
ARCHIVE NHI Prices of Original Products Should Be Cut on Entry of Generics: Dr Sakurai
October 20, 2003
-
ARCHIVE Switch OTC Drugs to Revitalize OTC Drug Market: Dr Fujii
October 20, 2003
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 20, 2003
-
ARCHIVE Increased Copayment Rate Has Affected Medical Care in Nearly 60% of Patients
October 20, 2003
-
ARCHIVE Dr Tsuboi Not to Run for JMA President Election
October 20, 2003
-
ARCHIVE To Create Extroverted Company to Survive: Mr Hayama of Tanabe
October 20, 2003
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 20, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
October 20, 2003
-
ARCHIVE 1 in 3 VDT Workers Suffer from Dry Eyes: JOA
October 20, 2003
-
ARCHIVE Kyowa Hakko Licenses KW-3902 Adenosine A1 Receptor Antagonist
October 20, 2003
-
ARCHIVE RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 20, 2003
-
ARCHIVE Number of Accesses via "MR-kun" Exceeded 200,000 in September
October 20, 2003
-
ARCHIVE Japanese Healthcare Q&A (2)
October 20, 2003
-
ARCHIVE AstraZeneca Reorganizes Primary Care Business Unit
October 20, 2003
-
ARCHIVE Korosho WG Hears 7 Bodies on Deregulation of OTC Drug Sales
October 20, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…